Möchten Sie immer auf dem neuesten Stand bleiben?

Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients...

Abivax présente ses résultats financiers du T1 2026 et les données à trois ans de l’étude 108, un essai d’extension ouvert de phase 2a/2b évaluant l’obéfazimod après réduction de dose dans la RCH ...

BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3...

These findings reinforce the importance of continuing to deepen our understanding of the underlying biology that drives both growth and resistance.

VANCOUVER, British Columbia, May 20, 2026 (GLOBE NEWSWIRE) -- Grey Matters Health Inc. (the “Company” or “Grey Matters”) (CSE: GREY) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company,...

Oncology focused biotech to utilise 4basebio’s opDNA® technology to support Phase II clinical trial of immunotherapy candidate Multi-year, seven-figure revenue stream reflecting increased commercial...

After a thorough process, management are pleased to undertake this pivotal step for GMP production of PRP for the upcoming Phase 1 FIH clinical study

Matisse Pharmaceuticals announces U.S. FDA clearance of the company’s Investigational New Drug (IND) application for isupartob sodium

Mestag Therapeutics Announces the First Patient Dosed with MST-0312 in the Phase I STARLYS Trial

Khondrion announced that the first patient has been dosed in the Phase II SON4PEM study evaluating sonlicromanol in Post-COVID.